129O - EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive l...

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session ESMO-IASLC Best Abstracts
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter Tao Jiang
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors T. Jiang, C. Zhou
  • Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN


Our previous study demonstrated that liver metastases (LM) were the negative predictive and prognostic factor in EGFR-mutant NSCLC patients (Pts) treated with EGFR-TKIs, suggesting that additional treatment is warranted. Recently, several studies reported that local therapy could significantly improve progression-free survival (PFS) in NSCLC Pts with oligometastatic or oligoprogressive disease. This study aimed to investigate whether addition of local therapy to EGFR-TKIs could provide survival benefit in EGFR-mutant NSCLC Pts with oligometastatic or oligoprogressive LM.